Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment

Methotrexate (MTX) is one of the staples of pediatric acute lymphoblastic leukemia (ALL) treatment. MTX targets the folate metabolic pathway (FMP). Abnormal function of the enzymes in FMP, due to genetic aberrations, leads to adverse drug reactions. The aim of this study was to investigate variants...

Full description

Bibliographic Details
Main Authors: Nikola Kotur, Jelena Lazic, Bojan Ristivojevic, Biljana Stankovic, Vladimir Gasic, Lidija Dokmanovic, Nada Krstovski, Goran Milosevic, Dragana Janic, Branka Zukic, Sonja Pavlovic
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Genes
Subjects:
pharmacogenomics
pediatric ALL
methotrexate
pharmacokinetics
drug-related toxicity
Online Access:https://www.mdpi.com/2073-4425/11/4/468

Internet

https://www.mdpi.com/2073-4425/11/4/468

Similar Items